| scholarly article | Q13442814 |
| P50 | author | Jesús Giraldo | Q38324244 |
| P2093 | author name string | N Vrang | |
| Helmut Buschmann | |||
| Jörg Holenz | |||
| Gonzalo Romero | |||
| Xavier Codony | |||
| David Heal | |||
| Alberto Dordal | |||
| Angels Fisas | |||
| Petrus Johan Pauwels | |||
| R V Sørensen | |||
| Ramon Mercé | |||
| P2860 | cites work | Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor | Q24310557 |
| Obesity and insulin resistance | Q24607078 | ||
| Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors | Q28141153 | ||
| CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity | Q28242954 | ||
| 5-ht6 receptors | Q28245286 | ||
| A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation | Q28263452 | ||
| Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y | Q28363106 | ||
| Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects | Q29617231 | ||
| Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands | Q31153950 | ||
| Current and investigational antiobesity agents and obesity therapeutic treatment targets | Q34344786 | ||
| Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task | Q34427413 | ||
| 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist | Q34490069 | ||
| Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial | Q34494637 | ||
| Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study | Q34556870 | ||
| Thermogenic effects of sibutramine and its metabolites | Q35028643 | ||
| Pharmacotherapy for dyslipidaemia – current therapies and future agents | Q35574960 | ||
| Serotonin receptor ligands and the treatment of obesity | Q35767986 | ||
| The hardship of obesity: a soft-wired hypothalamus | Q36108709 | ||
| The impact of obesity on psychological well-being | Q36252482 | ||
| A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. | Q38298172 | ||
| Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice | Q38333962 | ||
| Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling | Q40611704 | ||
| Sibutramine: a novel new agent for obesity treatment | Q41026257 | ||
| Influence of sibutramine on energy expenditure in African American women | Q43594329 | ||
| Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice | Q44193713 | ||
| Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice | Q44318882 | ||
| Postmarketing surveillance of abuse liability of sibutramine | Q44332680 | ||
| Oral administration of the 5-HT2Creceptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. | Q44400212 | ||
| The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance | Q46595047 | ||
| Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia | Q46807918 | ||
| Abuse liability assessment of sibutramine, a novel weight control agent | Q47247058 | ||
| Weight stigmatization and ideological beliefs: relation to psychological functioning in obese adults | Q47380525 | ||
| The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction | Q57420301 | ||
| Chronic fenfluramine treatment: effects on body weight, food intake and energy expenditure | Q72570091 | ||
| Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice | Q77094351 | ||
| Obesity | Q77665702 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| P304 | page(s) | 973-83 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats | |
| P478 | volume | 148 |
| Q36346938 | 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms |
| Q37809899 | 5-HT6 Medicinal Chemistry |
| Q38449992 | 5-hydroxytryptamine medications for the treatment of obesity |
| Q37780550 | 5-hydroxytryptamine subtype 6 receptor modulators: a patent survey |
| Q38027891 | 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives |
| Q30657759 | A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities |
| Q38760655 | AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation |
| Q37872282 | Advances in the design of 5-HT6 receptor ligands with therapeutic potential |
| Q24602751 | Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats |
| Q37387204 | Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists |
| Q33857698 | Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet |
| Q43221126 | Comparison of rimonabant and sibutramine treatment effects on food compulsion in rats |
| Q39768889 | Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel? |
| Q39028557 | Distribution of cells responsive to 5-HT₆ receptor antagonist-induced hypophagia |
| Q34111024 | E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. |
| Q33567269 | Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats |
| Q51564207 | Extended N-Arylsulfonylindoles as 5-HT₆ Receptor Antagonists: Design, Synthesis & Biological Evaluation. |
| Q36273778 | Idalopirdine - a small molecule antagonist of 5-HT6 with therapeutic potential against obesity |
| Q34847404 | Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht(6) receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task |
| Q38627971 | Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease. |
| Q33737233 | JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, reduces food preference for fat. |
| Q42323374 | Metabolic and Cardiovascular Benefits and Risks of EMD386088-A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor |
| Q47175680 | Modeling energy intake and body weight effects of a long-acting amylin analogue |
| Q85945448 | Modeling energy intake by adding homeostatic feedback and drug intervention |
| Q35952274 | Neuronal ciliary signaling in homeostasis and disease |
| Q33607984 | New central targets for the treatment of obesity |
| Q38205485 | Novel thiazole derivatives: a patent review (2008 - 2012. Part 2). |
| Q24658013 | Pharmacological targeting of the serotonergic system for the treatment of obesity |
| Q42633021 | Selective serotonin receptor stimulation of the medial nucleus accumbens differentially affects appetitive motivation for food on a progressive ratio schedule of reinforcement |
| Q40190491 | Stable expression of adenylyl cyclase 2 leads to the functional rescue of human 5-HT6 receptor in a CHODUKX cell line |
| Q41910031 | The 5-HT₂C receptor agonist, lorcaserin, and the 5-HT₆ receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour. |
| Q37694654 | The medicinal chemistry of 5-HT6 receptor ligands with a focus on arylsulfonyltryptamine analogs |
| Q37987116 | The serotonin-6 receptor as a novel therapeutic target |
| Q35589958 | The utility of animal models to evaluate novel anti-obesity agents |
| Q38757203 | Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin-concentrating Hormone Receptor 1 Antagonist |
Search more.